Tirzepatide represents a dual GLP-1 and GIP receptor agonist that works through a stepwise dosing protocol, typically starting at 2.5 mg weekly and titrating upward every four weeks
Ingredients: Water(Aqua), Niacinamide, Cetyl Ethylhexanoate, Caprylic/Capric Triglyceride, Glycerin, 1,2-Hexanediol, Pentaerythrityl Tetraethylhexanoate, Ethylhexyl Palmitate, Polyglyceryl-3 Distearate, Lithospermum Erythrorhizon Root Extract, Octyldodecanol, C12-14 Alketh-12, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Tromethamine, Glyceryl Stearate Citrate, Glyceryl Stearate, Ethylhexylglycerin, Prunus Amygdalus Amara (Bitter Almond) Kernel Oil, Adenosine, Camellia Sinensis Leaf Extract, Disodium EDTA, Pyrus Malus (Apple) Leaf Extract, Trehalose, Saccharide Hydrolysate, Panthenol, Cyanocobalamin, Vanilla Planifolia Fruit Extract, Jasminum Officinale (Jasmine) Flower Water, Butylene Glycol, Tranexamic Acid, Polyglyceryl-10 Laurate, Ascorbic Acid, Alpha-Arbutin, Hydrogenated Lecithin, Sodium Hyaluronate, Hyaluronic Acid, Sodium Hyaluronate Crosspolymer, Hydrolyzed Sodium Hyaluronate, Hydrolyzed Hyaluronic Acid, Glutathione, Sodium Acetylated Hyaluronate, Hydroxypropyltrimonium Hyaluronate, Ceramide NS, Ceramide NP, Ceramide EOP, Ceramide AP
Tirzepatide activates both GLP-1 and GIP receptors, while Semaglutide targets only the GLP-1 receptor
The gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) enrichment analyses were carried out
Real Peptides labels every vial with precise peptide content to eliminate guesswork
